バージニアにおける膀胱癌の臨床試験
バージニア内の拠点で、膀胱癌に関する24件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07000084Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- University of Virginia Cancer Center, Charlottesville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- Bon Secours Saint Francis Medical Center, Midlothian
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06770582A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Urology of Virginia ( Site 0125), Virginia Beach
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06833073Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07061964Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Virginia Oncology Associates, Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07566156Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care, Blacksburg
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care, Low Moor
- 他4件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- NEXT Oncology Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Virginia Oncology Associates (VOA) ( Site 8002), Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07419295A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- USO - Virginia Oncology Associates, Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07217171Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Potomac Urology, Alexandria
- Urology of Virginia, Virginia Beach
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06567743The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他5件
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Virginia Urology, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/24更新 · NCT05951179Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Norfolk
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07129993Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- Bon Secours Saint Francis Medical Center, Midlothian
- Bon Secours Saint Mary's Hospital, Richmond
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07097142LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- University of Virginia Comprehensive Cancer Center, Charlottesville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/07更新 · NCT04752722Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- University of Virginia Health System, Charlottesville
- Local Institution - 0188, Norfolk
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/07/29更新 · NCT07106762An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Falls Church
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Inova Schar Cancer Institute, Fairfax
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/22更新 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
- University of Virginia, Charlottesville
被験者募集中
18歳〜90歳 · 全性別 · 2024/12/16更新 · NCT05790850ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。